We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current BPMC market cap is 6.17B. The company's latest EPS is USD -1.0498 and P/E is -92.04.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 71.96M | 96.12M | 138.16M | 128.19M | 146.37M |
| Operating Income | -105.11M | -78.82M | -43.05M | -48.01M | -41.2M |
| Net Income | -110.92M | 89.14M | -50M | -56.27M | -49.96M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 793.74M | 180.08M | 204.04M | 249.38M | 508.82M |
| Operating Income | 308.71M | -641.98M | -537.52M | -486.28M | -212.04M |
| Net Income | 313.88M | -644.09M | -557.52M | -506.98M | -67.09M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.05B | 1.04B | 1.2B | 1.2B | 1.18B |
| Total Liabilities | 918.64M | 727.79M | 883.32M | 886.5M | 881.15M |
| Total Equity | 130.61M | 310.69M | 320.24M | 313.15M | 298.67M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.72B | 1.25B | 1.35B | 1.05B | 1.18B |
| Total Liabilities | 248.31M | 281.49M | 835.23M | 918.64M | 881.15M |
| Total Equity | 1.47B | 970.74M | 514.68M | 130.61M | 298.67M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -436.85M | -101.51M | -149.59M | -163.22M | -192.59M |
| Investing | 274.04M | 77.13M | -111.16M | -81.21M | -47.5M |
| Financing | 119.23M | 66.96M | 244.98M | 263.35M | 273.11M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 387.04M | -298.65M | -502.28M | -436.85M | -192.59M |
| Investing | -434.25M | -225.86M | -149.54M | 274.04M | -47.5M |
| Financing | 617.76M | 50.72M | 561.81M | 119.23M | 273.11M |
| Market Cap | 6.17B |
| Price to Earnings Ratio | -92.04 |
| Price to Sales Ratio | 12.13 |
| Price to Cash Ratio | 60.53 |
| Price to Book Ratio | 20.67 |
| Dividend Yield | - |
| Shares Outstanding | 63.91M |
| Average Volume (1 week) | 723.08k |
| Average Volume (1 Month) | 1.05M |
| 52 Week Change | -1.61% |
| 52 Week High | 121.90 |
| 52 Week Low | 80.675 |
| Spread (Intraday) | 12.72 (13.11%) |
| Company Name | Blueprint Medicines Corporation |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.blueprintmedicines.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
